Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Our site is under planned maintenance. At this time, you will not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Emerging Research & Trial Strategies for Progressive Multiple Sclerosis

WEBINAR

Only

Emerging Research & Trial Strategies for Progressive Multiple Sclerosis

Monday, October 4, 2021, 10:25 AM - 5:20 PM EDT

Webinar

Presented By

The New York Academy of Sciences

Biogen

 

Despite being the most common progressive neurologic disease in young adults worldwide, no treatment is available for progressive forms of multiple sclerosis (MS). Furthermore, advances in disease modifying therapeutics for relapsing remitting MS have little to no efficacy for progressive MS. This is due in part to an incomplete understanding of the disease mechanism and lack of validated outcome measures for clinical trials.

To advance scientific understanding and therapies to treat progressive MS patients, this 1-day virtual symposium will convene physician-scientists, academics, industry leaders, and clinicians to discuss recent basic and clinical research and offer new targets and modalities to be tested as treatments. Session topics include research on innate immune response and cells as therapeutic targets, advances in biomarkers to assess disease progression and monitor response to therapy, and insights into Phase 2 and Phase 3 clinical trial design.

Registration

Member
$85
Nonmember Academia, Faculty, etc.
$105
Nonmember Corporate, Other
$130
Nonmember Not for Profit
$105
Nonmember Student, Undergrad, Grad, Fellow
$40
Member Student, Post-Doc, Fellow
$30

Scientific Organizing Committee

Katerina Akassoglou, PhD
Katerina Akassoglou, PhD

Gladstone Institutes and UCSF

Peter A. Calabresi, MD
Peter A. Calabresi, MD

Johns Hopkins Medicine

Olga Ciccarelli
Olga Ciccarelli, PhD

University College London

Robert Fox
Robert Fox, MD

Cleveland Clinic

Jerome Hanna
Jerome Hanna, MB BCh, BAO

Biogen

Jason Mendoza
Jason Mendoza, PhD

Biogen

Melanie Brickman Borchard
Melanie Brickman Borchard, PhD, MSc

New York Academy of Sciences

Keynote Speaker

Bruce Trapp, PhD
Bruce Trapp, PhD

Cleveland Clinic

Speakers

Martina Absinta, PhD
Martina Absinta, PhD

Johns Hopkins University and Vita-Salute San Raffaele University, Milan

Jeremy Chataway, MA, PhD, FRC
Jeremy Chataway, MA, PhD, FRC

University College London

Robin Franklin, PhD
Robin Franklin, PhD

University of Cambridge

Francisco Quintana, PhD
Francisco Quintana, PhD

Harvard University and Brigham and Women’s Hospital

Maria Pia Sormani, PhD
Maria Pia Sormani, PhD

University of Genoa

Bruce Trapp, PhD
Bruce Trapp, PhD

Cleveland Clinic

Katerina Akassoglou
Katerina Akassoglou, PhD

Gladstone Institutes and UCSF

Peter A. Calabresi, MD
Peter A. Calabresi, MD

Johns Hopkins Medicine

Olga Ciccarelli, PhD
Olga Ciccarelli, PhD

University College London

Robert Fox, MD
Robert Fox, MD

Cleveland Clinic

Claudia F. Lucchinetti, MD​
Claudia F. Lucchinetti, MD​

Mayo Clinic

Monday

October 04, 2021

10:25 AM

WELCOME REMARKS

Speakers

Melanie Brickman Borchard, PhD, MSc
New York Academy of Sciences
Jerome Hanna, MB BCh BAO, MRCS, MFPM
Biogen
10:40 AM

KEYNOTE PRESENTATION: Pathogenesis of Neurological Disability in MS

Speakers

Chair: Jerome Hanna, MB BCh BAO, MRCS, MFPM
Biogen
Bruce Trapp, PhD
Cleveland Clinic

Multiple sclerosis (MS) is a demyelinating disease of the CNS and the major cause of permanentneurological disability in young adults. Immune modifying therapies reduce disease progression inRRMS, but have minimal effect on the irreversible disability caused by axonal and neurodegenerationduring progressive MS. This presentation will review settings/mechanisms that are thought to be responsible for axonal and neurodegeneration in progressive MS including degeneration of chronicallydemyelinated axons, cortical demyelination and expansion of chronic active white matter lesions.Increased energy demands of axonal conduction set the stage for degeneration of chronicallydemyelinated axons. Reduced ATP production associated with mitochondrial pathology increaseaxoplasmic Ca+, activate proteolytic enzymes, and eventually cause axonal degeneration. Corticaldemyelination causes neuronal and axonal loss and is more prominent in PMS than in RRMS.Mechanisms proposed for subpial cortical demyelination include meningeal B cells and corticalmicroglia, but not infiltrating peripheral immune cells. Microglia are associated with the expansion ofchronic active white matter lesions. These microglia have a distinct molecular phenotype compared tomicroglia in myelinated white matter and microglial that line the border of subpial cortical lesions.Compartmentation of microglial phenotypes, neuronal/axonal mitochondria and meningeal B cells areattractive targets for future PMS therapeutics.

11:25 AM

Break

SESSION I: Research and Targets

11:40 AM

Astrocyte Pathogenic Activities in Progressive MS

Speaker

Francisco J. Quintana, PhD
Harvard University and Brigham and Women’s
12:05 PM

Blood-Brain Barrier and Neurotoxic Innate Immunity in MS

Speaker

Katerina Akassoglou, PhD
Gladstone Institutes and UCSF
12:30 PM

Remyelination and Aging — Reversing the Ravages of Time

Speaker

Robin Franklin, PhD
University of Cambridge
12:55 PM

Break

SESSION II: Short Talks Selected from Submitted Abstracts

1:45 PM

Short Talk 1

Speaker

Speaker to Be Selected
1:55 PM

Short Talk 2

Speaker

Speaker to Be Selected

SESSION III: Biomarkers and Endpoints

2:05 PM

Fluid Biomarkers of MS Disease Activity and Treatment Response

Speaker

Peter A. Calabresi, MD
Johns Hopkins Medicine
2:30 PM

Imaging Biomarkers of the Spinal Cord in MS

Speaker

Olga Ciccarelli, PhD
University College London
2:55 PM

Paramagnetic Rim Lesion Assessment in Progressive Multiple Sclerosis

Speaker

Martina Absinta, PhD
Johns Hopkins University and Vita-Salute San Raffaele University, Milan
3:20 PM

Progressive MS: Pathologic and Therapeutic Implications

Speaker

Claudia F. Lucchinetti, MD
Mayo Clinic
3:45 PM

Break

SESSION IV: Trial Considerations for Progressive MS

4:00 PM

Clinical Trial Design for Progressive MS Trials

Speaker

Maria Pia Sormani, PhD
University of Genoa
4:25 PM

Insights into Phase II Trials in Progressive MS

Speaker

Jeremy Chataway, MA, PhD, FRC
University College London
4:50 PM

Insights into Phase III Trials in Progressive MS

Speaker

Robert Fox, MD
Cleveland Clinic
5:15 PM

Closing Remarks

Speakers

Melanie Brickman Borchard, PhD, MSc
New York Academy of Sciences
Jason Mendoza, PhD
Biogen
5:20 PM

End of Day